Gilead Details Its HCV Dominance As AbbVie Seeks Meaningful Market Position
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. continues to maintain a dominant share in the hepatitis C market, while AbbVie Inc. tries to capitalize on a subordinate but still viable position in the indication. Gilead provided some granularity during its July 28 earnings call on how it has built such a huge edge in HCV sales and what its next tasks are, just as AbbVie used its July 24 call to assure investors it still has room to grow. The latter hopes an imminent Japanese approval and a second-generation regimen will boost its HCV business.